CT-SCOUTTM is now available in three dermatological indications: atopic dermatitis, Psoriasis and hidradenitis suppurativa
Paris, France, July 07, 2022: CTMA, a clinical research service company that is working to change the way patients are detected for clinical trials, announced that it is expanding its CT-SCOUTTM technology offering into a third therapeutic area – Dermatology. CT-SCOUTTM, the company’s multi-device platform that allows health care professionals (HCP) to identify trial candidates, will now be available for sites, sponsors and contract research organizations (CROs) in three dermatological indications: Atopic dermatitis, Psoriasis and Hidradenitis Suppurativa
Pierre Pellier, CEO of CTMA, said, ” We are very pleased to expand our platform by adding this third therapeutic area. This allows us to support more patients, studies, sites and sponsors around the world. Atopic dermatitis, Psoriasis and Hidradenitis Suppurativa are chronic, exhausting diseases that affect a large patient population for whom clinical trials can be an important alternative therapeutic solution.”
Building on its successful experience in inflammatory bowel disease (IBD) and its recent expansion into rheumatology, CTMA plans to continue expanding its offering to include additional therapeutic areas in order to accelerate clinical research. Currently, a majority of clinical trials are delayed and up to 10% of trials are never completed. CTMA’s technology allows healthcare providers to use an app in real-time alongside a patient, to efficiently identify trials running at the site that will match the patient’s profile.
Patients suffering from Atopic dermatitis, Psoriasis and Hidradenitis Suppurativa are still looking for new therapies as there is a large unmet medical need. Ultimately, the goal of CTMA’s app-based technology is to help bring innovative therapies to patients faster.
CTMA is a clinical research service company that is working to change the way patients are detected for clinical trials. Based in Paris, the company has developed an innovative solution to address the critical patient detection problem that affects most clinical trials. In 2014, CTMA launched its innovative, patented methodology and application, to increase recruitment in clinical studies. Since then, CTMA has successfully worked with the larger sponsors in inflammatory bowel disease (IBD) – ulcerative colitis (UC) and Crohn’s disease (CD), and also, in rheumatology (Rheumatoid Arthritis, Ankylosing Spondylarthritis and Psoriatic Rheumatism.) where it demonstrated that sites equipped with its solution can recruit by up to four times more than non-equipped sites.
More than 250 investigational sites have benefited from this unique solution so far. For more information, please visit: www.ctma.fr